Short Interest in Talphera, Inc. (NASDAQ:TLPH) Decreases By 38.1%

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 52,400 shares, a decrease of 38.1% from the August 31st total of 84,700 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 58,700 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC bought a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera at the end of the most recent reporting period. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Stock Performance

Shares of TLPH traded up $0.05 during mid-day trading on Friday, reaching $0.86. 54,060 shares of the company were exchanged, compared to its average volume of 88,383. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61. The business has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $0.98. The stock has a market capitalization of $14.60 million, a PE ratio of -0.97 and a beta of 0.33.

Talphera (NASDAQ:TLPH) last announced its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts predict that Talphera will post -0.73 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Talphera in a research note on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.